In the phase III TROPiCS-02 trial (NCT03901339) (Study Details Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Metastatic Breast Cancer ClinicalTrials.gov, 2023), the safety and efficacy of sacituzumab govitecan were assessed in HR+/HER2– advanced breast cancer. Here, ERBB2 is linked to breast carcinoma.